Peter Dobranowski @PDobrano

MSc, PhD(c) | Precision Microbiome IBD opinions my own linkedin.com/in/peter-dobra… Ottawa, Ontario Joined April 2012

Tweets

264
Followers

299
Following

596
Likes

4K

Peter Dobranowski @PDobrano

4 weeks ago

What's next: we used our ex vivo microbiome culturing platform (RapidAIM) to personalize RS in clinical trials. Trials are complete and analyses are ongoing. A big thank you to all collaborators, technicians, and patients and their families for enabling this work.

0 0 0 50 0

View Details

Peter Dobranowski @PDobrano

4 weeks ago

Our new paper adds: - RS-specific fermentation profiles - Microbiomes from kids with IBD ferment RS with high inter-individual variability - Broad microbiome functions are activated by RS, beyond butyrate (nucleic acids, fatty acids, amino acids, and derivatives)

1 0 0 55 0

View Details

Peter Dobranowski @PDobrano

4 weeks ago

Happy to announce the first chapter of my PhD is published open access in @Nature_NPJ: nature.com/articles/s4152… 🧵

1 0 4 79 1

View Details

Peter Dobranowski @PDobrano

5 months ago

@srmbeauroy @bottomlineibd @policritic Strong disease-level conclusions, with residuals perhaps explained by e.g. diet x gene x microbiome x psych x medication interactions. I anticipate future PREdiCCt studies will leverage these interactions to cut through noise and arrive closer to individualized predictions.

0 0 2 18 0

View Details

Peter Dobranowski @PDobrano

5 months ago

@IldikoMe Nonetheless, metagenomics on the removed appendices seems like low-hanging fruit to predict responders/non-responders.

1 0 2 35 0

View Details

Peter Dobranowski @PDobrano

5 months ago

@IldikoMe I was excited to read this as an indictment on the microbiome, but certainly tempered by the nuance - appendicectomy was adjunct to biologics, and 80% of the control group was given Tofa 10mg. E.g. outcomes would be different without adjunct biologics or with a 100% Upad control.

1 0 2 47 0

View Details

Erik Hoel @erikphoel

9 months ago

Writing this made me feel better this week. I hope reading it makes you feel better. theintrinsicperspective.com/p/we-are-not-l…

10 21 129 52K 56

View Details

Peter Dobranowski @PDobrano

12 months ago

This is not a totally surprising outcome of precision medicine (and may be useful in certain contexts): patients predicted to respond to a therapy may simply fare better without the therapy to begin with.

0 0 3 58 0

View Details

Peter Dobranowski @PDobrano

12 months ago

Clinical remission was more likely in “predicted responders” (32%) than non-stratified patients (26%). But, clinical remission was also more likely in “predicted responders” randomized to the placebo group (11%) than non-stratified placebo patients (1%).

1 0 3 63 0

View Details

Peter Dobranowski @PDobrano

12 months ago

2025 @NEJM study by @bruce_sands1 et al reports efficacy and safety of anti-TL1A (Tulisokibart) in moderate-severe #UC. Notably, they evaluated patient stratification using a gene-variant machine learning algorithm. nejm.org/doi/full/10.10…

1 2 5 400 0

View Details

Peter Dobranowski @PDobrano

12 months ago

Given that gut barrier dysfunction can precede IBD diagnosis by years, the role of butyrate remains a critical part of IBD research: as a biomarker of disease, and therapeutic lever through personalized diet, next-gen probiotics, and FMT. 10.1016/j.clnu.2022.10.024

0 0 2 38 0

View Details

Peter Dobranowski @PDobrano

12 months ago

But, this vicious cycle parallels a virtuous cycle – treating these dysbiotic mice with butyrate reversed DUOX2 upregulation, epithelial permeability, and subclinical inflammation.

1 0 2 31 0

View Details

Peter Dobranowski @PDobrano

12 months ago

From 2025 @Gut_BMJ, Hazime et al @ibddocmaria untangle more of DUOX2’s role in early / subclinical #IBD, with new evidence of #butyrate’s role in maintaining gut homeostasis gut.bmj.com/content/early/…